Mergers & acquisitions
Gyroscope Therapeutics, headquartered in Stevenage, UK, is merging with Ambler, Pennsylvania-based Orbit Biomedical. They will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.
Bionovate Technologies, Corp. announced that during the last fiscal year’s reporting period, it acquired a patent from Ramot University in Tel Aviv, Israel as part of the company’s strategy to develop non-invasive cancer imaging and identification systems.
Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets
Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.
Masy BioServices announced it has acquired Metrology Laboratories Inc., a calibration services provider located in Rockaway, New Jersey.
Shares of Bristol-Myers Squibb are up slightly this morning after the proposed $74 billion acquisition of Celgene gained some significant support over the weekend. That support has caused at least one opposition group to withdraw from the fight.
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
Supporters and those opposed to the proposal are marshaling their forces ahead of the April 12 shareholder vote.
The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
PRESS RELEASES